Interferon alpha-2b biosimilar - Amega Biotech

Drug Profile

Interferon alpha-2b biosimilar - Amega Biotech

Alternative Names: Interferon Alfa-2b biosimilar - Amega Biotech

Latest Information Update: 23 Aug 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amega Biotech
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase Unknown Condylomata acuminata; Follicular lymphoma; Hairy cell leukaemia; Hepatitis C; Kaposi's sarcoma; Malignant melanoma

Most Recent Events

  • 14 Aug 2013 Investigation in Condylomata acuminata in Argentina (Parenteral)
  • 14 Aug 2013 Investigation in Follicular lymphoma in Argentina (Parenteral)
  • 14 Aug 2013 Investigation in Hairy cell leukaemia in Argentina (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top